These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
753 related articles for article (PubMed ID: 18284311)
1. Disease progression and the need for neuroprotection in glaucoma management. Varma R; Peeples P; Walt JG; Bramley TJ Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311 [TBL] [Abstract][Full Text] [Related]
2. History of neuroprotection and rationale as a therapy for glaucoma. Levin LA; Peeples P Am J Manag Care; 2008 Feb; 14(1 Suppl):S11-4. PubMed ID: 18284310 [TBL] [Abstract][Full Text] [Related]
3. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I]. Rokicki W; Dorecka M; Romaniuk W Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296 [TBL] [Abstract][Full Text] [Related]
4. [Glaucoma--neurodegenerative disease]. Tataru LC; Bogdănici CM Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1120-5. PubMed ID: 20191885 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotection in Glaucoma: Animal Models and Clinical Trials. Almasieh M; Levin LA Annu Rev Vis Sci; 2017 Sep; 3():91-120. PubMed ID: 28731838 [TBL] [Abstract][Full Text] [Related]
9. Should we treat the brain in glaucoma? Gupta N; Yücel YH Can J Ophthalmol; 2007 Jun; 42(3):409-13. PubMed ID: 17508036 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotection in glaucoma - Is there a future role? Baltmr A; Duggan J; Nizari S; Salt TE; Cordeiro MF Exp Eye Res; 2010 Nov; 91(5):554-66. PubMed ID: 20800593 [TBL] [Abstract][Full Text] [Related]
11. [Glaucoma as primary optic neuropathy]. Nicolae A; Stefan C Oftalmologia; 2001; 54(4):5-8. PubMed ID: 12035602 [TBL] [Abstract][Full Text] [Related]
12. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation. Schwartz M; London A Prog Brain Res; 2008; 173():375-84. PubMed ID: 18929122 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Hains BC; Waxman SG Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495 [TBL] [Abstract][Full Text] [Related]
14. Clinical trials in neuroprotection. Whitcup SM Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119 [TBL] [Abstract][Full Text] [Related]
15. Molecular and cell-based approaches for neuroprotection in glaucoma. Lebrun-Julien F; Di Polo A Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011 [TBL] [Abstract][Full Text] [Related]
16. Preventing vision loss from glaucoma: putting data from clinical trials into practice. Schoenleber DB Mo Med; 2005; 102(1):51-4. PubMed ID: 15754618 [TBL] [Abstract][Full Text] [Related]
17. [The dawn of neuroprotective therapy for glaucomatous optic neuropathy]. Yamamoto T Nippon Ganka Gakkai Zasshi; 2001 Dec; 105(12):866-83. PubMed ID: 11802458 [TBL] [Abstract][Full Text] [Related]
18. In glaucoma, should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders? Haefliger IO; Fleischhauer JC; Flammer J Eye (Lond); 2000 Jun; 14 ( Pt 3B)():464-72. PubMed ID: 11026975 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Chan HC; Chang RC; Koon-Ching Ip A; Chiu K; Yuen WH; Zee SY; So KF Exp Neurol; 2007 Jan; 203(1):269-73. PubMed ID: 17045262 [TBL] [Abstract][Full Text] [Related]